[The use of stepwise antibacterial therapy of community-acquired pneumonia].

The need of stepwise antibacterial therapy of community-acquired pneumonia is an important indicator of patient's condition and provides clinical and economic advantages for both the patients and the medical facility. High compliance with this approach is promoted by the regular retrospective assessment of its advantages and the availability ofproper dosage forms of the prescribed antibiotics.

[Infectious exacerbation of chronic obstructive pulmonary disease: prospects for high-dose levofloxacin therapy].

This open comparative randomized study of efficacy, safety, and pharmacoeconomic characteristics of hilifox-750 (750 mg daily for 5 days) and amoxiclav 2X (875/125 mg twice daily for 10 days) included 60 patients with chronic obstructive pulmonary disease (COPD). Duration of the study was 6 months. Medians of age and smoking index in the group treated with hilifox-750 were 63.5 yr (59, 67) and 30 packs/yr (15, 60) respectively. The treatment reduced cough, apnea, sputum volume and pyoptysis with comparative rates of normalization of body temperature and peripheral leukocyte counts in both groups. Helifox-750 promoted decrease in coughing and apnea within the first three days of therapy. 28 (93%) and 26 (87%) patients recovered by day 4 of helifox and amoxiclav therapy (F-test p = 0.67). Both drugs showed comparable bacteriological efficacy. They were not different in terms of side effect frequency that were mild, resolved spontaneously and did not require withdrawal of therapy. Helifox had advantages over amoxiclav in that it reduced duration of antibacterial therapy to 5 days and of temporary incapacity to 12 days (vs 14); moreover, it needs to be taken only once daily.

[Prophylaxis of acute respiratory viral infections in organized communities].

There are presented the data of placebocontrolled research, which was realized for the purpose of analyze of effectiveness and safety of using of agent "Kagocel" for prophylaxis of acute respiratory virus infections among military servicemen of call-up service. Among persons, got kagocel, was marked a low number of ARVI in comparison with persons, got placebo. The highest prophylactic effect was marked for the first 2 month of getting the agent. A mild disease (ARVI) flow was marked among persons, got placebo. It has approved it self in low frequency of complications. There was shown a grand economic benefit of prophylactic using of kogocel course of treatment.

[Pharmacoeconomic aspects of therapy of pneumonia in a hospital]. / Farmakoékonomicheskie aspekty lecheniia pnevmonii v usloviiakh gospitalia.

In the article the assessment of hospital treatment cost of patients with pneumonia under conditions of district military clinical hospital is given. The analysis of cost of complete treatment course has shown that the most expensive is therapy of patients with severe and moderately severe pneumonia (6083 and 4608 rubles). Depending on pneumonia severity the treatment expenses increases on the average by 49%. The main treatment expenses in pneumonia under hospital conditions are medical-and-diagnostic, which determine the other items of expenditure.